Neuroinflammation Pathway

Migration, Crosslink

📖

Neuroinflammation Pathway

active

wiki page Created: 2026-04-02T07:19:54 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-neuroinflammation-pathwa

📖 Wiki Page

mechanisms3067 wordssynced 2026-04-02

Neuroinflammation Pathway

The neuroinflammation pathway is a central mechanism in neurodegenerative diseases, involving the coordinated activation of innate immune cells in the brain in response to pathological insults. While acute neuroinflammation serves a protective role, chronic neuroinflammation contributes to neuronal dysfunction and death.

Overview

Neuroinflammation is initiated by:

DAMPs (Damage-Associated Molecular Patterns) — ATP, HMGB1, nucleic acids released from damaged [neurons](/entities/neurons)
PAMPs (Pathogen-Associated Molecular Patterns) — viral/bacterial components in rare infectious triggers
Endogenous misfolded proteins — [Aβ](/proteins/amyloid-beta), [tau](/proteins/tau), [α-synuclein](/proteins/alpha-synuclein) aggregates acting as danger signals

These triggers activate pattern recognition receptors (PRRs) on [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), triggering a signaling cascade that produces pro-inflammatory cytokines, chemokines, and reactive oxygen/nitrogen species[@ransohoff2016].

Signaling Cascade

...

Neuroinflammation Pathway

The neuroinflammation pathway is a central mechanism in neurodegenerative diseases, involving the coordinated activation of innate immune cells in the brain in response to pathological insults. While acute neuroinflammation serves a protective role, chronic neuroinflammation contributes to neuronal dysfunction and death.

Overview

Neuroinflammation is initiated by:

DAMPs (Damage-Associated Molecular Patterns) — ATP, HMGB1, nucleic acids released from damaged [neurons](/entities/neurons)
PAMPs (Pathogen-Associated Molecular Patterns) — viral/bacterial components in rare infectious triggers
Endogenous misfolded proteins — [Aβ](/proteins/amyloid-beta), [tau](/proteins/tau), [α-synuclein](/proteins/alpha-synuclein) aggregates acting as danger signals

These triggers activate pattern recognition receptors (PRRs) on [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), triggering a signaling cascade that produces pro-inflammatory cytokines, chemokines, and reactive oxygen/nitrogen species[@ransohoff2016].

Signaling Cascade

Mermaid diagram (expand to render)

Key Players

Pattern Recognition Receptors

| Receptor | Ligands | Signaling Adapters | Disease Relevance |
|----------|---------|-------------------|-------------------|
| TLR4 | Aβ, HMGB1, LPS | MyD88, TRIF | AD, PD [@zhang2013] |
| TLR9 | DNA, Aβ aggregates | MyD88 | AD, MS |
| RAGE | Aβ, HMGB1, S100 | NF-κB, MAPK | AD, PD, ALS [@lyman2014] |
| NLRP3 | Aβ, MSU, ATP | ASC, caspase-1 | AD, PD [@zhou2011] |

Pro-inflammatory Cytokines

| Cytokine | Source Cells | Primary Effects | Therapeutic Target |
|----------|--------------|------------------|-------------------|
| TNF-α | Microglia, astrocytes | Neuronal apoptosis | Etanercept, Infliximab |
| IL-1β | Microglia, monocytes | Tau phosphorylation [@kitazawa2005] | Anakinra, Canakinumab |
| IL-6 | Microglia, astrocytes | Acute phase response | Tocilizumab |
| IL-18 | Microglia, macrophages | IFN-γ induction | Not tested |

Microglial Polarization: M1 vs M2

Microglia can adopt distinct activation states:

Mermaid diagram (expand to render)

M1 (Classical Activation)

Triggered by: IFN-γ, LPS, Aβ, TNF-α
Markers: CD16, CD32, CD86, iNOS
Function: Pro-inflammatory, cytotoxic

M2 (Alternative Activation)

Triggered by: IL-4, IL-13, IL-10, glucocorticoids
Markers: CD206, Arg1, YM1, Fizz1
Function: Anti-inflammatory, tissue repair

Disease-Associated Microglia (DAM)

Microglia adopt disease-specific phenotypes[@kerenshaul2017]:

Stage 1 DAM:

[TREM2](/proteins/trem2-protein)-independent
Downregulation of homeostatic genes
Upregulation of immune genes

Stage 2 DAM:

[TREM2](/genes/trem2)-dependent
Phagocytic genes upregulated
Lipid metabolism genes activated

Role in Specific Diseases

Alzheimer's Disease

Neuroinflammation is both a consequence and driver of AD pathology:

Aβ activates microglia via [TLR4](/entities/tlr4) and [NLRP3 inflammasome](/entities/nlrp3-inflammasome)[@halle2008]

IL-1β promotes [tau](/proteins/tau) phosphorylation via [CDK5](/proteins/cdk5-protein) and GSK3β

TNF-α enhances Aβ production through [BACE1](/entities/bace1) upregulation

Complement activation (C1q, C3) drives synaptic pruning

TREM2 variants (R47H, R62H) increase AD risk ~3x[@guerreiro2013]

Parkinson's Disease

α-Synuclein aggregates activate microglia via TLR2/TLR4

NLRP3 inflammasome is activated in PD substantia nigra[@fan2015]

Pro-inflammatory cytokines contribute to dopaminergic neuron death

Amyotrophic Lateral Sclerosis

Activated microglia surround motor neurons in ALS

NLRP3 and ASC specks are found in ALS spinal cord

[C9orf72](/entities/c9orf72) mutations cause innate immune dysregulation

Genetic Risk Factors

| Gene | Variant | Effect on Neuroinflammation | Disease |
|------|---------|----------------------------|---------|
| TREM2 | R47H, R62H | Loss of phagocytic function | AD |
| CD33 | rs3865444 | Increased expression | AD |
| CR1 | rs6653641 | Altered complement | AD |
| INPP5D | rs35349669 | Altered signaling | AD |

Therapeutic Targets

Anti-inflammatory Drug Strategies

| Target | Drug Class | Examples | Stage |
|--------|-----------|----------|-------|
| TNF-α | Monoclonal antibodies | Etanercept | Phase II |
| IL-1β | IL-1Ra | Anakinra | Phase II |
| NLRP3 | Inhibitors | MCC950 | Preclinical |
| COX-2 | NSAIDs | Celecoxib | Failed |

Microglial Modulation

TREM2 agonists — enhance phagocytosis
CD33 blockade — reduce activation
PPAR-γ agonists — shift phenotype

Biomarkers

CSF Biomarkers

| Biomarker | Change in Disease |
|-----------|------------------|
| IL-1β | Increased in AD, PD |
| IL-6 | Increased in AD |
| TNF-α | Increased in AD, PD |
| YKL-40 | Marker of gliosis |

PET Imaging

TSPO PET: Measures microglial activation[@varley2015]

Neuroinflammation and Synaptic Dysfunction

Chronic neuroinflammation directly damages synapses[@stevens2008]:

Complement-mediated pruning: C1q and C3 tag synapses
Microglial phagocytosis: Engulfment of synaptic material
Cytokine toxicity: Direct effects on synaptic proteins
Oxidative stress: Damage to synaptic membranes

Aging and Neuroinflammation

Microglial dystrophy: Age-related changes
Inflammaging: Chronic low-grade inflammation
Microglial priming: Enhanced inflammatory response
Reduced clearance: Declining phagocytic capacity

Cross-Linking to Other Mechanisms

[Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway) — Aβ activates microglia
[Tau Pathology Pathway](/mechanisms/tau-pathology-pathway) — Cytokines promote tau pathology
[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway) — [ROS](/entities/reactive-oxygen-species) from microglia

Microglia-Astrocyte Cross-Talk in Neuroinflammation

Bidirectional Signaling Networks

Microglia and astrocytes engage in extensive bidirectional communication that shapes the neuroinflammatory landscape in neurodegenerative diseases. This cross-talk operates through multiple signaling pathways that amplify or suppress inflammatory responses depending on the disease context and stage.

Key Crosstalk Mechanisms

Cytokine-Mediated Communication:

IL-1β Signaling: Activated microglia release IL-1β, which potently induces astrocyte reactivity and A1 neurotoxic phenotype formation. IL-1β signaling through IL-1R1 on astrocytes triggers NF-κB activation and production of additional inflammatory mediators, creating feed-forward amplification loops that drive chronic neuroinflammation.

TNF-α Signaling: Microglia-derived TNF-α promotes astrocyte production of pro-inflammatory cytokines including IL-6, CCL2, and CXCL10. TNF-α signaling through TNFR1/TNFR2 on astrocytes also contributes to blood-brain barrier disruption and peripheral immune cell recruitment.

IL-6 Family Cytokines: Microglia release IL-6 and related cytokines (LIF, CNTF) that activate STAT3 signaling in astrocytes, promoting reactive astrogliosis and modulating the balance between neuroprotective and neurotoxic phenotypes.

Paracrine Factor Signaling:

CX3CL1 (Fractalkine): The neuronally-expressed CX3CL1 signals through CX3CR1 on microglia to maintain homeostatic surveillance. Disruption of this signaling axis during neurodegeneration contributes to microglial priming and enhanced inflammatory responses.

CCL2 (MCP-1): Astrocyte-derived CCL2 recruits microglia to sites of injury and modulates microglial phagocytic activity. Reciprocally, microglia-derived factors regulate astrocyte CCL2 expression.

ATP and Purinergic Signaling: Damage-released ATP activates both microglia and astrocytes through P2X/P2Y receptors. Microglial ATP signaling promotes cytokine release, while astrocyte ATP signaling modulates calcium waves and glutamate homeostasis.

Complement System Crosstalk:

C1q Production: Astrocytes and microglia both produce complement component C1q, which tags synapses for elimination. Microglial CR3 receptor mediates engulfment of C1q-opsonized synaptic material.

C3 and C3aR Signaling: A1-reactive astrocytes upregulate C3, which signals through C3aR on neurons and microglia to promote synaptic dysfunction and microglial recruitment.

TREM2-Complement Interactions: TREM2 signaling modulates microglial response to complement-opsonized targets, linking innate immune recognition to phagocytic clearance.

Disease-Specific Cross-Talk Patterns

Alzheimer's Disease:

Aβ activates both microglia and astrocytes, creating synergistic inflammatory cascades
Microglial IL-1β drives astrocyte A1 phenotype formation
TREM2 deficiency impairs microglial clearance of complement-tagged synapses
Astrocyte-derived complement C1q amplifies microglial synaptic pruning

Parkinson's Disease:

α-Synuclein activates microglia via TLR2/TLR4, producing inflammatory cytokines
Astrocytes respond by adopting reactive phenotypes that contribute to dopaminergic neuron vulnerability
Microglia-astrocyte cross-talk contributes to慢性 neuroinflammation in substantia nigra

Amyotrophic Lateral Sclerosis:

Astrocyte C3 expression correlates with disease progression
Microglial complement contributes to motor neuron vulnerability
Non-cell autonomous toxicity through glia-neuron cross-talk

Therapeutic Implications

Targeting microglia-astrocyte cross-talk offers novel therapeutic strategies:

IL-1β blockade: Anakinra or canakinumab to prevent astrocyte activation

TREM2 modulation: Agonists to enhance microglial clearance function

Complement inhibition: C1q or C3 blocking antibodies to reduce synaptic pruning

Astrocyte phenotype modulation: Promote A2 neuroprotective phenotype

Microglia-Astrocyte Cross-Talk Flowchart

Mermaid diagram (expand to render)

Conclusion

Neuroinflammation represents both a consequence of neurodegenerative pathology and an active driver of disease progression. While anti-inflammatory therapies have largely failed, targeting specific pathways (TREM2, NLRP3) shows promise[@chen2023][@wang2024].

Recent Advances in Microglial Biology

Single-cell RNA sequencing has revolutionized our understanding of microglial heterogeneity in neurodegenerative diseases[@yang2024]. Disease-associated microglia (DAM) represent a distinct activation state characterized by upregulation of lipid metabolism genes and phagocytic markers. TREM2 plays a critical role in this transition, with loss-of-function variants significantly increasing AD risk[@song2023].

Emerging therapeutic strategies

CSF1R inhibition: Targeting microglial proliferation and survival through CSF1R blockade offers a novel approach to modulate the microglial compartment[@liu2024]
TREM2 modulation: Agonistic antibodies enhancing phagocytic function
NLRP3 inhibitors: Direct targeting of inflammasome activation

Neuroinflammatory Cytokines and Receptors Comparison

| Cytokine | Primary Source | Receptor | Signaling | Pro-inflammatory |
|----------|---------------|----------|----------|-----------------|
| IL-1β | Microglia, astrocytes | IL-1R1/IL-1R2 | MyD88, NF-κB | Yes |
| IL-6 | Microglia, astrocytes | IL-6R/gp130 | JAK/STAT | Context-dependent |
| TNF-α | Microglia, astrocytes | TNFR1/TNFR2 | NF-κB, JNK | Yes |
| IL-18 | Microglia | IL-18R | MyD88, NF-κB | Yes |
| IFN-γ | T cells, NK cells | IFNGR1/IFNGR2 | JAK/STAT | Yes |
| CCL2 | Astrocytes, microglia | CCR2 | Gαi | Chemoattractant |
| CX3CL1 | Neurons | CX3CR1 | Gαi | Anti-inflammatory |
| TGF-β | Astrocytes, microglia | TβRI/II | SMAD | Anti-inflammatory |

Microglial Phenotype Markers

| Marker | M1 (Pro-inflammatory) | M2 (Anti-inflammatory) |
|--------|----------------------|----------------------|
| CD16/32 | ↑ | ↓ |
| CD86 | ↑ | ↓ |
| CD206 | ↓ | ↑ |
| CD163 | ↓ | ↑ |
| iNOS | ↑ | ↓ |
| Arg1 | ↓ | ↑ |

Therapeutic Approaches

Failed Approaches

NSAIDs: COX-2 inhibitors failed in AD prevention[@group2014]
Minocycline: Failed in ALS and AD trials
TNF inhibitors: Limited CNS penetration

Emerging Strategies

TREM2 modulation: Agonistic antibodies
CSF1R inhibition: Targeting microglial proliferation
NLRP3 inhibitors: Direct inflammasome blockade
Metabolic modulation: Ketogenic diets, NAD+ boosters

Neuroinflammation in Specific Diseases

Multiple Sclerosis

Blood-brain barrier breakdown allows immune cell infiltration

CD4+ T cells drive autoimmune response

Microglial activation in demyelinating lesions

Complement-mediated damage to oligodendrocytes

Huntington's Disease

Mutant huntingtin activates microglia

NLRP3 inflammasome in striatal neurons

Cytokine release contributes to neurodegeneration

Frontotemporal Dementia

Microglial activation correlates with disease severity

TREM2 variants affect disease progression

Neuroinflammation in tau and TDP-43 pathology

Molecular Mechanisms

NF-κB Signaling

The NF-κB pathway is central to neuroinflammation[^14]:

Activation: TLRs, RAGE, TNFR trigger IKK complex
IκB degradation: Releases p65/p50 dimers
Nuclear translocation: Binds to κB response elements
Gene transcription: Pro-inflammatory cytokines, chemokines

MAPK Signaling

Mitogen-activated protein kinases:

p38 MAPK: Stress-activated, regulates cytokines
JNK: Jun kinase, apoptosis signaling
ERK: Growth factor signaling, can be protective

Inflammasome Activation

NLRP3 inflammasome formation[^15]:

Priming signal: NF-κB upregulates NLRP3, pro-IL-1β

Activation signal: ATP, ROS, crystals trigger assembly

ASC speck formation: Recruitment of ASC adapter

Caspase-1 activation: Cleaves pro-IL-1β, pro-IL-18

Pyroptosis: Inflammatory cell death

Biomarkers in Detail

Blood Biomarkers

| Biomarker | Source | Disease | Utility |
|-----------|--------|---------|---------|
| YKL-40 | Plasma | AD, MS | Gliosis marker |
| GFAP | Plasma | AD | Astrocyte activation |
| Neurofilament light | Plasma | ALS, AD | Neuronal damage |
| Tau | Plasma | AD | Neurodegeneration |

Imaging Biomarkers

PBR28 PET: TSPO binding in microglia[^16]
PK11195: Alternative TSPO ligand
FEPET: Monoamine oxidase B imaging

Genetics of Neuroinflammation

AD Risk Genes

| Gene | Function | Effect |
|------|----------|--------|
| TREM2 | Phagocytosis receptor | Variants increase risk |
| CD33 | Siglec receptor | Inhibits phagocytosis |
| CR1 | Complement receptor | Affects clearance |
| MS4A4E | Cell surface protein | Modulates signaling |

Epigenetic Regulation

DNA methylation of inflammatory genes
Histone modifications in microglia
Non-coding RNAs as regulators

Clinical Implications

Diagnostic Value

CSF cytokines: Support differential diagnosis
PET imaging: Assess disease activity
Blood markers: Screening and monitoring

Therapeutic Implications

Timing: Early intervention likely critical
Combination: Multiple targets may be needed
Personalization: Genetics may guide therapy

Research Directions

Emerging Areas

Single-cell sequencing of microglia

Spatial transcriptomics of inflammatory pathways

iPSC models of neuroinflammation

Organoid systems for drug testing

Biomarker Development

Multiplex platforms for cytokine panels
Ultrasensitive assays for blood detection
Longitudinal tracking of inflammation

References (continued)

[@group2014]: Group AI. [Neurinflammation prevention trials](https://pubmed.ncbi.nlm.nih.gov/24439487/). N Engl J Med. 2014;370(16):1583-1592.

[@diseaseassociated]:

Disease-Associated Microglia (DAM):

TREM2-dependent activation pathway
Upregulation of lipid metabolism genes
Phagocytic phenotype
Found in AD, ALS, MS

Aging Microglia:

Senescent phenotype
Secretory profile changes
Reduced phagocytosis
Enhanced inflammatory responses

Activated microglia subtypes:

CAMs: Conservative activation microglia
IQRMs: Injury-quickly responding microglia
ARM: Alternative activation microglia

Astrocyte Reactivity

Astrocytes undergo dramatic changes in disease[^18]:

Reactive astrogliosis:

Proliferation and hypertrophy
Upregulation of GFAP
Loss of domain organization
Gain of neurotoxic functions

A1 vs A2 phenotypes:

A1: Neurotoxic, induced by IL-1α, TNF, C1q
A2: Neuroprotective, induced by IL-4, IL-10

Oligodendrocyte Interactions

Myelin phagocytosis by microglia
Precursor cell dysfunction
Remyelination failure
Axonal metabolic support loss

Neuroinflammation and Proteinopathies

Interaction with Amyloid

Aβ drives inflammatory responses[^19]:

Direct activation of TLR4 on microglia

NLRP3 inflammasome assembly

Cytokine storm in microenvironment

Feedback loops amplify pathology

Interaction with Tau

Tau pathology induces inflammation[^20]:

Extracellular tau activates microglia

Cytokines promote phosphorylation

Spread via inflammatory mechanisms

Neuronal loss fuels chronic inflammation

Interaction with α-Synuclein

Parkinson's disease features[^21]:

Aggregates activate microglia

NLRP3 activation in substantia nigra

Dopaminergic neuron vulnerability

Progressive inflammatory cascade

Therapeutic Target Validation

Preclinical Models

APP/PS1 mice: Amyloid-driven inflammation
P301S tau mice: Tauopathy models
α-synuclein models: PD features
iPSC-derived microglia

Clinical Trial Design

Patient selection by inflammatory biomarkers
Endpoint selection beyond cognition
Imaging correlates for target engagement
Combination approaches may be needed

Systems Biology Approaches

Network Analysis

Gene regulatory networks in inflammation
Protein-protein interactions map pathways
Metabolic networks in activated glia
Cross-species comparisons for translation

Computational Models

Boolean networks of microglial activation
Ordinary differential equations for signaling
Agent-based models of cell interactions
Machine learning for biomarker discovery

Neuroinflammation Assessment

Histopathological Methods

IHC for cytokines and gliosis markers
RNA in situ hybridization for transcripts
Electron microscopy of glia
3D reconstruction of inflammatory foci

Molecular Methods

Bulk RNA-seq of brain tissue
Single-cell RNA-seq of microglia
Proteomics of CSF and brain
Metabolomics of inflammatory states

Future Perspectives

Precision Medicine

Genetic stratification based on inflammatory variants
Biomarker-driven patient selection
Targeted therapies for specific mechanisms
Combination regimens for synergistic effects

Prevention Strategies

Lifestyle modifications to reduce inflammation
Early intervention before symptom onset
Modifiable risk factors targeting
Longitudinal monitoring of at-risk individuals

Neuroinflammation Research Methods

In Vitro Approaches

Primary cultures of microglia
iPSC-derived glia
Organotypic slice cultures
Microfluidic devices for migration

In Vivo Imaging

Two-photon microscopy of mouse brain
Longitudinal PET of inflammation
Optogenetic control of microglial activity
Fiber photometry of calcium signals

Circadian Rhythm and Inflammation

Diurnal Variation

Inflammatory responses show daily variation[^23]:

Clock gene regulation of cytokines
Melatonin anti-inflammatory effects
Sleep disruption increases inflammation
Therapeutic timing considerations

Neuroinflammation and Sleep

Sleep deprivation activates microglia
Aβ accumulation during wakefulness
Glymphatic clearance during sleep
Bidirectional relationship

Sex Differences in Neuroinflammation

Hormonal Effects

Estrogen anti-inflammatory properties
Testosterone modulation of microglia
Menstrual cycle influences
Postmenopausal vulnerability

Clinical Implications

AD prevalence higher in women
PD progression differs by sex
Therapeutic response variations
Personalized approaches needed

Environmental Factors

Infections

Herpes simplex and AD risk
Systemic infections impact brain
Microbiome-gut-brain axis
Chronic viral infections

Toxins

Air pollution activates microglia
Pesticides and PD risk
Heavy metals neuroinflammation
Occupational exposures

Nutritional Influences

Dietary Components

Omega-3 fatty acids reduce inflammation
Polyphenols antioxidant effects
Vitamin D immunomodulation
Caloric restriction benefits

Metabolic Syndrome

Obesity increases brain inflammation
Type 2 diabetes cognitive risk
Insulin resistance glial dysfunction
Vascular contributions

Neuroinflammation Modeling

Mathematical Models

ODE-based cytokine dynamics
Stochastic activation models
Network-based inflammation maps
Patient-specific modeling

Machine Learning

Biomarker prediction from multi-omics
Image analysis of gliosis
Drug response modeling
Patient stratification algorithms

Clinical Trial Endpoints

Inflammatory Biomarkers

CSF cytokines as pharmacodynamic markers
Blood markers for easy monitoring
Imaging of microglial activation
Composite endpoints for inflammation

Clinical Measures

Cognitive trajectories as primary endpoint
Functional outcomes secondary measures
Quality of life assessments
Biomarker correlations

References (continued)

[@schafer2012]: Schafer DP. [Microglia sculpt neural circuits](https://pubmed.ncbi.nlm.nih.gov/22956841/). Neuron. 2012;73(5):874-878.

Spatiotemporal Pattern

Neuroinflammation follows predictable patterns[^24]:

- End-stage**: Compl

Regional Vulnerability

Hippocam- Substantia nigra**: PD-specific vulnerability
Motor cortex: ALS-specific patterns
Frontal cortex: FTD features

Therapeutic Resistance Mechanisms

Barrier Penetration

Blood-brain barrier limits drug delivery
Efflux transporters reduce brain concentrations
Inflammatory barrier changes during disease
Focused ultrasound for opening BBB

Target Selection

Multiple pathways involved
Redundant mechanisms compensate
Cell-type specificity challenges
Temporal targeting complexities

Emerging Research Techniques

Optogenetics

Light-controlled microglial activation
Circuit-specific manipulation
Temporal precision in studies
Translational potential

Chemogenetics

DREADDs for microglial modulation
Designer receptors for specific pathways
Non-invasive activation possible

Translational Challenges

Species Differences

Microglial markers vary between species
Inflammatory pathways evolutionarily conserved
Brain structure differences
Clinical translation failures

Model Limitations

Acute vs chronic inflammation differences
Genetic background effects
Environmental factors not replicated
Therapeutic timing challenges

Future Therapeutic Directions

Gene Therapy

Anti-inflammatory gene delivery
Microglial repopulation strategies
CRISPR targeting of variants
Viral vector approaches

Cell Therapy

Microglial transplantation
iPSC-derived glia
Engineered cells for repair
Immunomodulatory approaches

References (continued)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1
[Microglial Efferocytosis Enhancement via GPR32 Superagonists](/hypothesis/h-470ff83e) — 0.63 · Target: CMKLR1
[Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — 0.60 · Target: ALOX12
[Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — 0.58 · Target: ALOX15
[Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution](/hypothesis/h-f71a9791) — 0.57 · Target: GPR37
[Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — 0.47 · Target: ALOX5

Related Analyses:

[Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄

📖 View canonical wiki page →

Related Entities

mechanisms-neuroinflammation-pathway

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-neuroinflammation-pathway
kg_node_id	None
entity_type	mechanisms
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ddb2e039a5eb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-neuroinflammation-pathway'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

57

Outgoing

95

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neuroinflammation Pathway

Neuroinflammation Pathway

Overview

Signaling Cascade

Neuroinflammation Pathway

Overview

Signaling Cascade

Key Players

Pattern Recognition Receptors

Pro-inflammatory Cytokines

Microglial Polarization: M1 vs M2

M1 (Classical Activation)

M2 (Alternative Activation)

Disease-Associated Microglia (DAM)

Role in Specific Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Genetic Risk Factors

Therapeutic Targets

Anti-inflammatory Drug Strategies

Microglial Modulation

Biomarkers

CSF Biomarkers

PET Imaging

Neuroinflammation and Synaptic Dysfunction

Aging and Neuroinflammation

Cross-Linking to Other Mechanisms

Microglia-Astrocyte Cross-Talk in Neuroinflammation

Bidirectional Signaling Networks

Key Crosstalk Mechanisms

Disease-Specific Cross-Talk Patterns

Therapeutic Implications

Microglia-Astrocyte Cross-Talk Flowchart

Conclusion

Recent Advances in Microglial Biology

Emerging therapeutic strategies

Neuroinflammatory Cytokines and Receptors Comparison

Microglial Phenotype Markers

Therapeutic Approaches

Failed Approaches

Emerging Strategies

Neuroinflammation in Specific Diseases

Multiple Sclerosis

Huntington's Disease

Frontotemporal Dementia

Molecular Mechanisms

NF-κB Signaling

MAPK Signaling

Inflammasome Activation

Biomarkers in Detail

Blood Biomarkers

Imaging Biomarkers

Genetics of Neuroinflammation

AD Risk Genes

Epigenetic Regulation

Clinical Implications

Diagnostic Value

Therapeutic Implications

Research Directions

Emerging Areas

Biomarker Development

References (continued)

Astrocyte Reactivity

Oligodendrocyte Interactions

Neuroinflammation and Proteinopathies

Interaction with Amyloid

Interaction with Tau

Interaction with α-Synuclein

Therapeutic Target Validation

Preclinical Models

Clinical Trial Design

Systems Biology Approaches

Network Analysis

Computational Models

Neuroinflammation Assessment

Histopathological Methods

Molecular Methods

Future Perspectives